Clinical Trial

Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency

Study acronym: CAPtivate
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Determine the long-term safety of DTX301 following a single intravenous (IV) dose in adults with late-onset ornithine transcarbamylase (OTC) deficiency.
Protocol Amendment History 43 amendments
This ClinicalTrials.gov record has been amended 43 times since 2018-08-15; most recent amendment 2026-05-28.
Status change: Enrolling by Invitation → Active, Not Recruiting 2022-03-10
Status change: Not Yet Recruiting → Enrolling by Invitation 2018-09-10
Trial Details
NCT Number NCT03636438
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Ornithine Transcarbamylase (OTC) Deficiency
Enrollment 11 participants
Start Date 2018-08-30
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-01